NCT02430480View on ClinicalTrials.gov

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 3, 2015

Primary Completion Date

December 1, 2019

Study Completion Date

June 11, 2024

Conditions
Prostate Cancer
Interventions
DRUG

Goserelin

10.8mg administered subcutaneously every 12 weeks (2 doses)

DRUG

Enzalutamide

160mg orally, daily for 24 weeks

DEVICE

mpMRI

Multiparametric MRI - One at baseline and after 6 months of treatment

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02430480 - Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer | Biotech Hunter | Biotech Hunter